Drugs / CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05124171 | Dec 2021 → Dec 2022 | COVID-19 | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05124171 ↗ |
| Modality | Vaccine | “SP/GSK subunit B.1.351 vaccine” NCT05124171 ↗ |